Lasmiditan Addition for the Patients with POor Results of Triptan (LAPPORT)

Lasmiditan Addition for the Patients with POor Results of Triptan (LAPPORT) - Lasmiditan Addition for the Patients with POor Results of Triptan (LAPPORT)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050092

Enrollment

Registered

2023-01-22

Start date

2023-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

Lasmiditan 50mg will be taken for the patients with poor effects of triptan.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1: migraine 2: patient can evaluate and record the headache. 3: poor results of triptan 4: no prior use of Lasmiditan

Exclusion criteria

Exclusion criteria: 1: hemiplegic migraine, migraine with brainstem aura, triptane contraindication 2: tolerance to multiple triptan 3: continuous headache 4: complicated with other headache 5: other pain disorder, analgesic user 6: the patient whose doctor in charge determined as inappropriate to include this study.

Design outcomes

Primary

Measure	Time frame
The effects of additonal lasmiditan at 1, 2 and 4 hours after the intake will be evalulated by patients using NRS and HIT-6.	—

Countries

Japan

Contacts

Public ContactYasushi Shibata

University of Tsukuba, Mito Medical Center Neurosurgery/ Headache Clinic

yshibata@md.tsukuba.ac.jp0292312371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026